文献速递妇科

基于新鲜冷冻组织的高级别浆液性卵巢癌BRCA状态肿瘤检测的可行性

Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach.
PubMed 文献 · Gynecol Oncol · 2020-06-15

该研究在三级转诊中心连续纳入456例新诊断FIGO IIIC-IV期高级别浆液性卵巢癌患者,评估基于新鲜冷冻组织的BRCA筛查流程可行性。结果显示145例(31.8%)存在临床相关tBRCA变异,其中BRCA1致病性变异89例(61.4%)、BRCA2致病性变异56例(38.6%)。292例tBRCA野生型患者中88例接受gBRCA检测,86例(97.8%)确认为gBRCA野生型。肿瘤检测与gBRCA检测一致率为86.3%(209/242)。作者认为该流程可行且可靠。

要点

  • 新鲜冷冻组织BRCA筛查流程在高级别浆液性卵巢癌中可行且可靠。
  • 456例患者中145例(31.8%)检出临床相关tBRCA变异。
  • 292例tBRCA野生型中88例接受gBRCA检测,86例(97.8%)确认为gBRCA野生型。

核心结论

  • 基于新鲜冷冻组织的BRCA筛查流程可行且可靠,可扩大可能从PARP抑制剂最大获益的BRCA突变人群,同时不遗漏家族成员的级联检测,从而维持其预防作用。

研究设计与样本

  • 在三级转诊中心连续纳入456例新诊断FIGO IIIC-IV期高级别浆液性卵巢癌患者,所有接受肿瘤活检的患者均进行tBRCA检测。

主要发现

  • 145例(31.8%)检出临床相关tBRCA变异,其中BRCA1致病性变异89例(61.4%),BRCA2致病性变异56例(38.6%)。
  • 292例tBRCA野生型患者中88例接受gBRCA检测,86例(97.8%)确认为gBRCA野生型,1例(1.1%)为gBRCA意义不确定变异,1例(1.1%)为gBRCA突变。
  • 肿瘤检测与gBRCA检测的一致率为86.3%(209/242)。
  • 292例tBRCA野生型患者中13例(4.5%)通过生物信息学算法怀疑大基因组重排(LGRs),行多重连接依赖探针扩增(MLPA),仅1例证实致病性变异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: For many years, BRCA mutational status has only been considered as a predictor of ovarian cancer susceptibility and as a prognostic factor. Nonetheless, in the era of precision medicine, it has also become a predictive biomarker of response to platinum-based-chemotherapy and, more recently, to PARP-inhibitors, also in the frontline setting. We assessed the feasibility of a fresh frozen tissue-based-BRCA-screening workflow in a tertiary referral center. METHODS: We consecutively enrolled a series of 456 newly diagnosed FIGO-Stage IIIC-IV, high grade serous-ovarian cancer patients. All patients receiving tumor-biopsy underwent tBRCA-testing. RESULTS: Clinically relevant tissue-BRCA (tBRCA) variants were observed in 145 women (31.8%), particularly we recognized 89 (61.4%) patients with BRCA1-pathogenetic variants (PVs) and 56 women (38.6%) with BRCA2-PVs. Among 292 tBRCA wild-type (wt) patients, 88 cases were germline BRCA tested (gBRCA) and 86 (97.8%) were confirmed as gBRCAwt, while 1 (1.1%) had gBRCA variant of uncertain significance and 1 had gBRCA mutation (1.1%). The concordance of tumor test versus germline BRCA test was 86.3% (209/242). Large genomic rearrangements (LGRs) were suspected in 13/292 tBRCAwt patients (4.5%) by using bioinformatic algorithm and multiplex ligation-dependent probe amplification (MLPA) was performed, with evidence of PVs in only 1 case. CONCLUSIONS: Fresh-frozen tissue-based BRCA screening workflow is feasible and reliable. It allows to enlarge the BRCA mutated population that might receive PARPi with the greatest benefit, without missing cascade testing for family members and therefore, maintaining its preventive role.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Marchetti C, Minucci A, D'Indinosante M, et al. Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach. Gynecol Oncol. 2020. PMID: 32553590. doi:10.1016/j.ygyno.2020.06.479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。